Degarelix Acetate
FDA-approved product (powder, subcutaneous), marketed as Firmagon.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Prostate adenocarcinoma
- Prostate cancer
- Prostate carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other hormone antagonists and related agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA62.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis66.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Degarelix Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Galantamine HydrobromideExisting use: Alzheimer disease, Dementia89.6% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more69.3% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives68.0% AI-predicted activityagainst K. pneumoniaeLab records exist50+ registered studies
- ElvitegravirExisting use: HIV infection, HIV-1 infection, Viral disease60.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more57.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm56.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more56.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome56.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more54.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia52.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis52.2% AI-predicted activityagainst K. pneumoniae28 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
NCT07455903 · start 2026-07-29
Registered record
- Registry ID
- NCT07455903
- Conditions
- Prostate Cancer; Localized Prostate Carcinoma
- Interventions
- Leuprolide; Degarelix; Relugolix; Triptorelin; Bicalutamide; 18-F Flotufolastat PSMA PET; Radical prostatectomy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-07-29
- Completion
- 2031-02
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; Localized Prostate CarcinomaInterventionLeuprolide; Degarelix; Relugolix; Triptorelin +3 morePhasePhase 2Registry statusRecruitingSupraphysiologic Testosterone Priming Induces Darolutamide Extended Response
NCT07142551 · start 2026-03-09
Registered record
- Registry ID
- NCT07142551
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Testosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; Darolutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2026-03-09
- Completion
- 2034-06-01
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Castration-resistant Prostate CancerInterventionTestosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; DarolutamidePhasePhase 2Registry statusRecruitingSafety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
NCT07389174 · start 2026-02
Registered record
- Registry ID
- NCT07389174
- Conditions
- mHSPC; mHNPC; Prostate Cancer Adenocarcinoma
- Interventions
- Standard Endocrine Therapy; LC-K76
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Not yet recruiting
- Start
- 2026-02
- Completion
- 2027-06
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionmHSPC; mHNPC; Prostate Cancer AdenocarcinomaInterventionStandard Endocrine Therapy; LC-K76PhaseEarly phase 1Registry statusNot yet recruitingThe COSMYC Trial (COmbined Suppression of MYC)
NCT06922318 · start 2025-08-19
Registered record
- Registry ID
- NCT06922318
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-08-19
- Completion
- 2031-08-30
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Castration-resistant Prostate CancerInterventionZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analoguePhasePhase 2Registry statusRecruitingStereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
NCT06378866 · start 2024-06-03
Registered record
- Registry ID
- NCT06378866
- Conditions
- Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate Carcinoma
- Interventions
- Abiraterone; Apalutamide; Biospecimen Collection; Bone Scan; Computed Tomography; Darolutamide; Degarelix; Enzalutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Imaging; Patient Observation; Positron Emission Tomography; Prednisone; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Radiation Therapy; Image-Guided Therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2024-06-03
- Completion
- 2031-02-28
- Enrolment
- 532
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer; Biochemically Recurrent Prostate CarcinomaInterventionAbiraterone; Apalutamide; Biospecimen Collection; Bone Scan +17 morePhasePhase 2Registry statusRecruitingCardiometabolic Consequences of the Loss of Ovarian Function
NCT06264882 · start 2024-06-01
Registered record
- Registry ID
- NCT06264882
- Conditions
- Menopause; Estrogen Deficiency; Aging; Adiposity
- Interventions
- Degarelix; Transdermal Estradiol Patch; Transdermal Placebo Patch
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Recruiting
- Start
- 2024-06-01
- Completion
- 2028-08-31
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMenopause; Estrogen Deficiency; Aging; AdiposityInterventionDegarelix; Transdermal Estradiol Patch; Transdermal Placebo PatchPhasePhase 4Registry statusRecruitingTreatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
NCT06282588 · start 2023-12-13
Registered record
- Registry ID
- NCT06282588
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide; Darolutamide matched placebo; Radiotherapy; Zoladex 3.6Mg Implant; Zoladex LA; Decapeptyl sustained release 22.5 mg; Decapeptyl sustained release 11.25 mg; Depo-Eligard 45 mg; Depo-Eligard 22.5 mg; Depo-Eligard 7.5 mg; Firmagon 120 MG Injection; Firmagon 80 MG Injection; Docetaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Recruiting
- Start
- 2023-12-13
- Completion
- 2030-12-31
- Enrolment
- 493
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDarolutamide; Darolutamide matched placebo; Radiotherapy; Zoladex 3.6Mg Implant +9 morePhasePhase 2 / Phase 3Registry statusRecruitingDifluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06059118 · start 2023-10-04
Registered record
- Registry ID
- NCT06059118
- Conditions
- Prostate Cancer
- Interventions
- DFMO; testosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; Enzalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2023-10-04
- Completion
- 2029-11-30
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDFMO; testosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; EnzalutamidePhasePhase 2Registry statusRecruitingNeo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
NCT05617885 · start 2023-08-09
Registered record
- Registry ID
- NCT05617885
- Conditions
- Metastatic Prostate Cancer; Non-metastatic Prostate Cancer; Prostate Cancer
- Interventions
- Darolutamide; Abemaciclib; GNRH-A Leuprolide Acetate; GNRH-A Goserelin; Degarelix
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2023-08-09
- Completion
- 2026-06-01
- Enrolment
- 9
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Prostate Cancer; Non-metastatic Prostate Cancer; Prostate CancerInterventionDarolutamide; Abemaciclib; GNRH-A Leuprolide Acetate; GNRH-A Goserelin +1 morePhasePhase 1Registry statusCompletedEnhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
NCT05212857 · start 2022-04
Registered record
- Registry ID
- NCT05212857
- Conditions
- Prostate Cancer
- Interventions
- Leuprolide acetate; Goserelin acetate; Triptorelin acetate; Degarelix acetate; Abiraterone acetate; Apalutamide; Enzalutamide; Local treatment for primary lesion; Radiotherapy for primary lesion; Radiotherapy for metastatic lesion
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2022-04
- Completion
- 2024-09
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionLeuprolide acetate; Goserelin acetate; Triptorelin acetate; Degarelix acetate +6 morePhasePhase 2Registry statusUnknownA Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer
NCT05149131 · start 2022-01-17
Registered record
- Registry ID
- NCT05149131
- Conditions
- Metastatic Castration-sensitive Prostate Cancer
- Interventions
- ADT (Eligard®*) with or without treatment intensification
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2022-01-17
- Completion
- 2022-08-16
- Enrolment
- 960
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Castration-sensitive Prostate CancerInterventionADT (Eligard®*) with or without treatment intensificationPhaseNot recordedRegistry statusCompletedOvarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)
NCT05057546 · start 2021-11-22
Registered record
- Registry ID
- NCT05057546
- Conditions
- Menopause; Estrogen Deficiency; Women; Aging
- Interventions
- GnRH antagonist
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Active not recruiting
- Start
- 2021-11-22
- Completion
- 2025-07-28
- Enrolment
- 55
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMenopause; Estrogen Deficiency; Women; AgingInterventionGnRH antagonistPhasePhase 4Registry statusActive not recruitingA Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
NCT04455750 · start 2021-10-14
Registered record
- Registry ID
- NCT04455750
- Conditions
- Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Enzalutamide; Rucaparib camsylate; Placebo; Leuprolide Acetate; Goserelin Acetate; Degarelix; Quality-of-Life Assessment; Questionnaire Administration
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2021-10-14
- Completion
- 2027-09
- Enrolment
- 61
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 moreInterventionEnzalutamide; Rucaparib camsylate; Placebo; Leuprolide Acetate +4 morePhasePhase 3Registry statusActive not recruitingTalazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT04734730 · start 2021-05-04
Registered record
- Registry ID
- NCT04734730
- Conditions
- Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate; Bicalutamide; Degarelix; Goserelin Acetate; Leuprolide Acetate; Prednisone; Questionnaire Administration; Talazoparib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2021-05-04
- Completion
- 2027-08-23
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 moreInterventionAbiraterone Acetate; Bicalutamide; Degarelix; Goserelin Acetate +4 morePhasePhase 2Registry statusRecruitingStudy of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT04666129 · start 2021-02-18
Registered record
- Registry ID
- NCT04666129
- Conditions
- Metastatic Castration-Resistant Prostate Cancer; Metastatic Castration-Sensitive Prostate Cancer; Non-Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Relugolix; Abiraterone; Prednisone; Methylprednisolone; Apalutamide; Docetaxel
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2021-02-18
- Completion
- 2024-05-28
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Castration-Resistant Prostate Cancer; Metastatic Castration-Sensitive Prostate Cancer; Non-Metastatic Castration-Resistant Prostate CancerInterventionRelugolix; Abiraterone; Prednisone; Methylprednisolone +2 morePhasePhase 1Registry statusCompleted